GV-971

Summary

Gv-971 (CHEMBL4650397) is a phase-3 clinical-stage unknown; indicated across 1 condition including alzheimer disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 1 condition
• Clinical trials: 6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4650397
Name	GV-971
Type	Unknown
Max phase	3

Also known as: Gv-971, GV-971, HS971, Oligomannurarate(971)

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
Alzheimer disease	3	MONDO:0004975	MONDO:0004975

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE4	2
PHASE1	2
PHASE3	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05908695	PHASE4	RECRUITING	An Efficacy and Safety Study of Sodium Oligomannate (GV-971) for the Treatment of Alzheimer’s Disease
NCT05430867	PHASE4	UNKNOWN	Efficacy and Safety of Memantine and Sodium Oligomannate in Patients With Moderate to Severe Alzheimer’s Disease
NCT04520412	PHASE3	SUSPENDED	A Study of Sodium Oligomannate (GV-971) in Participants With Mild to Moderate Alzheimer’s Disease
NCT02986529	PHASE1	COMPLETED	A Study to Assess the Bioavailability of Oral Sodium Oligo-mannurarate (GV-971) in Healthy Chinese Male Subjects
NCT03715114	PHASE1	UNKNOWN	A Study to Assess the Safety and Pharmacokinetics of Oral Sodium Oligo-mannurarate (GV-971) in Healthy Chinese Subjects
NCT05114499	Not specified	UNKNOWN	Efficacy and Safety of Donepezil and Sodium Oligomannate in Patients With Mild to Moderate Alzheimer’s Disease

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).